SOHO Italy 2020 Virtual Meeting

VJHemOnc was the official media partner of the 2nd SOHO Italy 2020 Virtual Meeting which took place on the 22-24th of September 2020.

This virtual three-day meeting brought together leading SOHO experts and Italian researchers in acute leukemias, MPNs, and MDS, with the aims of consolidating the Italian Hematology-SOHO partnership.

Watch the meeting on-demand below!

Day One

Day one of the meeting featured sessions on acute lymphoblastic leukemia (ALL).

Session I: State of the art in ALL

ALL: State of the art in MD Anderson Cancer Center: Hagop Kantarjian
ALL: State of the art in Europe: Giovanni Martinelli
Optimizing adult and elderly frontline ALL therapy: Role of immunochemotherapy: Elias Jabbour
ALL: Ph-like and new genetic subtypes and treatment implications: Marina Konopleva

Session I

Session II: Novel treatment approaches in ALL

CAR T-cells therapy: novel generation, fast-off, dual CAR T-cells: Josep-Maria Ribera
Novel therapeutic strategies on acute leukemia based on synthetic lethality: Andrea Ghelli Luserna di Rorà

Session II

Session III: Beyond ALL and near future

Diagnostic approaches for Ph-like B-ALL: Sergej Konoplev
Morphology in acute leukemias and hematologic malignancies: Gina Zini
Monoclonal antibodies: real-life and new combination trials: Cristina Papayannidis
Novel monoclonal antibodies combinations and near future of ALL in Italy: Francesco Lanza

Session III

Day Two

Day two of the meeting featured sessions on acute myeloid leukemia (AML).

Session IV: Individualized treatment in AML

Integrated transcriptomic and genomic sequencing identifies prognostic constellations of driver mutations in AML and MDS: Illaria Iacobucci
Proapoptotic pathways in AML: Sara Galimberti
Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients: Roberto Lemoli
Assessment of MRD in AML and integrating MRD into treatment: role of new techniques: Francesco Buccisano

Session IV

Session V: State of the art in AML

How I treat AML in MD Anderson Cancer Center: Hagop Kantarjian
Incorporating novel antibodies as target therapies in the treatment of older AML: Farhad Ravandi
Updates in immunotherapy and FLT3 inhibitors in AML: Naval Daver
Maintenance in AML – State of the art: Farhad Ravandi
How I manage elderly AML in MD Anderson Cancer Center: Tapan Kadia

Session V

Session VI: AML - Old certainties vs. new frontiers

Role of allogeneic transplant in novel agents era: Attilio Olivieri
Role of postSCT maintenance in AML: Alessandra Sperotto
Environment-mediated drug resistance in AML: Claudio Cerchione
Phase 4 studies in Spain: Adolfo De La Fuente

Session VI

Day Three

Day three of the meeting featured sessions on multiple myeloma (MM), lymphoma, chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPNs), and myelodysplastic disorders (MDS).

Session VII: Managing multiple myeloma in the era of novel agents

Genetic profiling of multiple myeloma in the novel agents era: Niccolo Bolli
How I treat smoldering MM: Maria-Victoria Mateos
How I manage unfit/frail patients: Daniele Derudas
Importance of imaging in the era of novel agents: Elena Zamagni

Session VII

Session VIII: Multiple myeloma - novel agents & ASCT vs CAR-T

Role of autologous transplant in MM in the novel agents era: Maria T. Petrucci
CAR T-cell therapies in MM: Massimo Martino
New drugs on the horizon: Francesco Di Raimondo

Session VIII

Session IX: State of the art in multiple myeloma

Multiple myeloma: state of the art in the USA: Kenneth Anderson
Multiple myeloma: state of the art in Europe: Claudio Cerchione
Near future of MM in Europe: Maria-Victoria Mateos
Near future of MM in the USA: Kenneth Anderson

Session IX

Session X: State of the art in non-Hodgkin lymphoma

How I manage DLBCL lymphoma in USA: Peter Martin
How I manage follicular, mantle cell and marginal lymphoma in Italy: Stefano Luminari

Session X

Session XI: Hodgkin lymphoma and the biology of lymphoma

How I manage Hodgkin disease in the USA: John Leonard
Challenges and new opportunities to manage Waldenstrom disease in Italy: Alessandra Tedeschi
Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma: Enrico Derenzini
Near future of Hodgkin lymphomas: Antonello Pinto

Session XI

Session XII: Chronic myeloid leukemia

How I manage CML in Italy: Giuseppe Saglio
Treatment-free remission where and when?: Michele Malagola
TFR: lights and shadows: Elisabetta Abruzzese

Session XII

Session XIII: New insights in MPNs

Management of myeloproliferative neoplasms: Srdan Verstovsek

Session XIII

Session XIV: State of the art in MDS

State of the art in the USA – Emerging frontline HMA based regimens: Guillermo Garcia-Manero
Patient-centred approach for the treatment of MDS: importance of quality of life: Esther Oliva

Session XIV